Advanced search    

Search: authors:"Alexander J. Thompson"

13 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Markers of Inflammation and Risk of Coronary Heart Disease

Cardiovascular disease is the leading cause of global mortality, with coronary heart disease (CHD) its major manifestation. Although inflammation, the body’s response to noxious stimuli, is implicated in several stages of CHD development, the relevance of circulating levels of markers of inflammation to CHD risk remains uncertain. This review summarizes available epidemiological...

Markers of Inflammation and Risk of Coronary Heart Disease

Cardiovascular disease is the leading cause of global mortality, with coronary heart disease (CHD) its major manifestation. Although inflammation, the body’s response to noxious stimuli, is implicated in several stages of CHD development, the relevance of circulating levels of markers of inflammation to CHD risk remains uncertain. This review summarizes available epidemiological...

Markers of Inflammation and Risk of Coronary Heart Disease

Cardiovascular disease is the leading cause of global mortality, with coronary heart disease (CHD) its major manifestation. Although inflammation, the body’s response to noxious stimuli, is implicated in several stages of CHD development, the relevance of circulating levels of markers of inflammation to CHD risk remains uncertain. This review summarizes available epidemiological...

Markers of Inflammation and Risk of Coronary Heart Disease

Cardiovascular disease is the leading cause of global mortality, with coronary heart disease (CHD) its major manifestation. Although inflammation, the body’s response to noxious stimuli, is implicated in several stages of CHD development, the relevance of circulating levels of markers of inflammation to CHD risk remains uncertain. This review summarizes available epidemiological...

“B in IT” - a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool

Background The current model of care for the treatment of chronic hepatitis B (CHB) in Australia is through specialist Hepatology or Infectious Diseases clinics, and limited accredited primary care practices. Capacity is limited, and less than 5% of Australians living with CHB currently access therapy. Increasing treatment uptake is an urgent area of clinical need. Nucleos(t)ide...

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B

Cynthia Wat 0 4 Bernadette Surujbally 0 Alexander J. Thompson 0 Isabelle Chemin, Centre de Recherche en Cancerologie de Lyon, FRANCE 0 Current address: Roche Innovation Center Shanghai , Pudong, Shanghai ... ) Acknowledgments The authors thank the patients in this study for consenting to sample analysis. Author Contributions Conceptualization: Lai Wei, Hua He, Cynthia Wat, Bernadette Surujbally, Alexander J. Thompson

Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection

. Predictors of fibrosis progressionÐAnalysis of non-SVR and untreated patients. Author Contributions Conceptualization: Alexander J. Thompson, Paul V. Desmond. Data curation: Swee Lin G. Chen Yi Mei, Britt ... Christensen, Georgina Cunningham, Lucy McDonald, David Iser, Tin Nguyen. Formal analysis: Swee Lin G. Chen Yi Mei, Britt Christensen, Paul V. Desmond. Investigation: Alexander J. Thompson. Methodology: Swee

Interferon-free combination therapies for the treatment of hepatitis C: current insights

Interferon-free combination therapies for the treatment of hepatitis C: current insights Jacinta A Holmes, Alexander J Thompson Department of Gastroenterology, St Vincent's Hospital, University of

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort

Aim Despite effective treatment for recent hepatitis C (HCV) infection, side-effects and adherence concerns limit its use among people who inject drugs (PWID). This study evaluated health-related quality of life (HRQoL) and social functioning following infection and during recent HCV treatment. Methods The Australian Trial of Acute Hepatitis C studied the natural history and...

The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service

Background Hepatitis C treatment uptake in Australia is low. To increase access to hepatitis C virus treatment for people who inject drugs, we developed a community-based, nurse-led service that linked a viral hepatitis service in a tertiary hospital to primary care clinics, and resulted in hepatitis C treatment provision in the community. Methods A retrospective cohort study of...

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Stuart K. Roberts Simone I. Strasser Alexander J. Thompson Joji Toyota Seung Woon Paik John M. Vierling Anna L. Zignego David Cohen Fiona McPhee Megan Wind‑Rotolo Subasree Srinivasan 0 Matthew Hruska

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes

Background. A recent genome-wide association study reported a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate (ITPA) gene and hemolytic anemia in patients infected with hepatitis C virus (HCV) receiving pegylated interferon and ribavirin. We investigate these polymorphisms in a cohort of human immunodeficiency virus (HIV)/HCV–coinfected...